Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC

被引：1
|
作者：
Weng, C. [1 ]
Tang, K. [2 ]
Jin, S. [3 ]
Zhou, C. [4 ]
Yao, Y. [5 ]
Su, J-W. [1 ]
Chen, H. [6 ]
Liu, K. [7 ]
Li, Y. [8 ]
Yang, J. [1 ]
机构：
[1] Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangzhou, Peoples R China
[2] Sun Yat sen Univ, Affiliated Hosp 1, Resp & Crit Care Med Dept, Guangzhou, Peoples R China
[3] Chinese Acad Med Sci, Shenzhen Ctr, Canc Hosp, Natl Canc Ctr,Natl Clin Res Ctr Canc, Shenzhen, Peoples R China
[4] Guangzhou Med Univ, Affiliated Hosp 1, Resp Med, State Key Lab Resp Dis, Guangzhou, Peoples R China
[5] Jinan Univ, Shenzhen Peoples Hosp, Dept Oncol, Shenzhen, Peoples R China
[6] Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangzhou, Peoples R China
[7] Dongguan Peoples Hosp, Dongguan Inst Clin Canc Res, Dongguan Key Lab Precis Diag & Treatment Tumors, Dongguan, Peoples R China
[8] Sichuan Univ, West China Hosp, West China Sch Med, Dept Thorac Oncol, Chengdu, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.638
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
560P
引用
收藏
页码：S1688 / S1688
页数：1
相关论文
共 27 条
  • [1] Response to the Combination of Osimertinib, Dabrafenib, and Trametinib in Leptomeningitis From EGFR-Mutant NSCLC With Acquired BRAF V600E Mutation: A Case Report
    Valet, Orion
    Swalduz, Aurelie
    Boussageon, Maxime
    Buisson, Adrien
    Avrillon, Virginie
    Mastroianni, Benedicte
    Perol, Maurice
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (06):
  • [2] Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient
    Maurício Fernando Silva Almeida Ribeiro
    Franciele Hinterholz Knebel
    Fabiana Bettoni
    Rodrigo Saddi
    Karina Perez Sacardo
    Felipe Sales Nogueira Amorim Canedo
    João Victor Machado Alessi
    Andrea Kazumi Shimada
    José Flávio Gomes Marin
    Anamaria Aranha Camargo
    Artur Katz
    npj Precision Oncology, 5
  • [3] Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient
    Silva Almeida Ribeiro, Mauricio Fernando
    Knebel, Franciele Hinterholz
    Bettoni, Fabiana
    Saddi, Rodrigo
    Sacardo, Karina Perez
    Nogueira Amorim Canedo, Felipe Sales
    Machado Alessi, Joao Victor
    Shimada, Andrea Kazumi
    Gomes Marin, Jose Flavio
    Camargo, Anamaria Aranha
    Katz, Artur
    NPJ PRECISION ONCOLOGY, 2021, 5 (01)
  • [4] Response to the combination of dabrafenib, trametinib and osimertinib in a patient with EGFR-mutant NSCLC harboring an acquired BRAFV600E mutation
    Zhou, Fei
    Zhao, Wencheng
    Chen, Xiaoxia
    Zhang, Jie
    Zhou, Caicun
    LUNG CANCER, 2020, 139 : 219 - 220
  • [5] Efficacy and tolerability of osimertinib with dabrafenib and trametinib in BRAF V600E acquired EGFR-mutant non-small cell lung cancer: a case series
    Lu, Kevin
    Tse, Victoria
    Altaie, Ghaith
    Husain, Hatim
    JOURNAL OF THORACIC DISEASE, 2024, 16 (08) : 5379 - 5387
  • [6] Acquired BRAF V600E Mutation Mediated Resistance to Osimertinib and Responded to Osimertinib, Dabrafenib, and Trametinib Combination Therapy
    Huang, Yihua
    Gan, Jiadi
    Guo, Kunbin
    Deng, Yangyang
    Fang, Wenfeng
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : E236 - E237
  • [7] Metastatic NSCLC with G719X/S781I EGFR-mutations with acquired BRAF V600E mutation - response to Osimertinib, Dabrafenib and Trametinib
    Urbanska, E. M.
    Sorensen, J. B.
    Melchior, L. C.
    Santoni-Rugiu, E.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S642 - S642
  • [8] Overcoming acquired osimertinib-resistance in EGFR-mutant advanced non-small lung cancer mediated by activating BRAF V600E mutation.
    Abdulla, Diana S. Y.
    Scheffler, Matthias
    Kobe, Carsten
    Persigehl, Thorsten
    Schmidt, Matthias
    Fassunke, Jana
    Merkelbach-Bruse, Sabine
    Michels, Sebastian Yves Friedrich
    Nogova, Lucia
    Koleczko, Sophia
    Fischer, Rieke Nila
    Riedel, Richard
    Drzezga, Alexander
    Buettner, Reinhard
    Wolf, Juergen
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Molecular Characteristics of BRAF Mutations in EGFR Mutant NSCLC after Progression on EGFR TKIs and Response to Combination Targeted Therapy
    Fang, W.
    Hu, J.
    Huang, Y.
    Xu, C.
    Wang, W.
    Yao, G.
    Shao, Y. W.
    Zhang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S628 - S629
  • [10] Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib
    Ho, Chao-Chi
    Liao, Wei-Yu
    Lin, Chih-An
    Shih, Jin-Yuan
    Yu, Chong-Jen
    Yang, James Chih-Hsin
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (03) : 567 - 572
123